These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 32698693)

  • 21. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
    Das S; Sarmah S; Lyndem S; Singha Roy A
    J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An in-silico pharmacophore-based molecular docking study to evaluate the inhibitory potentials of novel fungal triterpenoid Astrakurkurone analogues against a hypothetical mutated main protease of SARS-CoV-2 virus.
    Nag A; Dasgupta A; Sengupta S; Lai TK; Acharya K
    Comput Biol Med; 2023 Jan; 152():106433. PubMed ID: 36565483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (M
    Kumar SB; Krishna S; Pradeep S; Mathews DE; Pattabiraman R; Murahari M; Murthy TPK
    Comput Biol Med; 2021 Jul; 134():104524. PubMed ID: 34090015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
    Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
    Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
    Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
    Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
    In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluations of FDA-approved drugs targeting 3CLP of SARS-CoV-2 employing a repurposing strategy.
    Ahmad SS; Khalid M
    Comb Chem High Throughput Screen; 2022 Aug; ():. PubMed ID: 35975855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.
    Samdani MN; Morshed N; Reza R; Asaduzzaman M; Islam ABMMK
    Mol Divers; 2023 Jun; 27(3):1067-1085. PubMed ID: 35690957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of COVID-19 protease and HIV inhibitors interactions.
    Tran L; Tam DNH; Elhadad H; Hien NM; Huy NT
    Acta Pharm; 2022 Mar; 72(1):1-8. PubMed ID: 36651526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular docking, pharmacophore modelling, MD simulation and
    Oluyori AP; Olanipekun BE; Adeyemi OS; Egharevba GO; Adegboyega AE; Oladeji OS
    J Biomol Struct Dyn; 2023 Mar; 41(4):1510-1525. PubMed ID: 34996336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential SARS-CoV-2 RdRp inhibitors of cytidine derivatives: Molecular docking, molecular dynamic simulations, ADMET, and POM analyses for the identification of pharmacophore sites.
    M A Kawsar S; Hosen MA; Ahmad S; El Bakri Y; Laaroussi H; Ben Hadda T; Almalki FA; Ozeki Y; Goumri-Said S
    PLoS One; 2022; 17(11):e0273256. PubMed ID: 36441684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phytochemicals against SARS-CoV as potential drug leads.
    Swain SS; Panda SK; Luyten W
    Biomed J; 2021 Mar; 44(1):74-85. PubMed ID: 33736953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and
    Krishna Cheerala VS; Ghanta P; Neelakantan SC
    RSC Adv; 2021 Dec; 11(62):39328-39342. PubMed ID: 35492479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.